OralParenteralDosed ingredientTherapeutic flag Cosmetic cross-reference

Sodium Benzoate

CAS 532-32-1

Sodium Benzoate (CAS 532-32-1) is a Phase 4 pharmaceutical compound with 3 bioactivity targets and 147 adverse event associations.

SOURCE NLM DailyMed
Label records
0
SOURCE EMBL-EBI ChEMBL
Bioactivity
4
SOURCE DrugCentral
Adverse signals
147
SOURCE IUPHAR/BPS
PubMed IDs
0
SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name
Sodium Benzoate
CAS Number
532-32-1
UNII
OJ245FE5EU
InChIKey
WXMKPNITSTVMEF-UHFFFAOYSA-M
ChEMBL ID
CHEMBL1356
Molecule Type
Small molecule
Source Match
EMBL-EBI ChEMBL (INCHIKEY)
dosed ingredientnatural productoralparenteraltherapeutic flag
SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Clinical Development Phase

Highest clinical development phase rendered from the matched compound identifier rows.

Phase 4 (Approved)
Approved or marketed human pharmaceutical use is represented in the source phase field.
ChEMBL CHEMBL1356 | Small molecule
SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

This substance also has a cosmetic safety profile →
SOURCE EMBL-EBI ChEMBL 4 bioactivity rows

Bioactivity & Target Interactions

Target-level activity records with assay counts, activity type, and measured value where present.

TargetActivity ValueAssaysOrganism
- Ki 39775 nM 4 -
Carbonic anhydrase 2
Enzyme
 Ki 4.52 - Homo sapiens
Carbonic anhydrase 4
Enzyme
 Ki 4.13 - Homo sapiens
Carbonic anhydrase
Enzyme
 Ki 4.61 - Candida albicans (strain SC5314 / ATCC MYA-2876)
SOURCE DrugCentral 11 associations

Adverse Event Associations

DrugCentral / FAERS disproportionality signal rows matched to this compound.

Reaction PTDrug AE LLRMedDRA
Creatinine renal clearance decreased 40 170.567 10011372
Sedation complication 35 151.706 10079741
Blood calcium decreased 40 147.556 10005395
Orthostatic hypotension 43 139.235 10031127
Cognitive disorder 41 118.782 10057668
Sedation 36 110.935 10039897
Hyperammonaemia 25 107.76 10020575
Depressed level of consciousness 39 103.948 10012373
Balance disorder 39 97.12 10049848
Mobility decreased 38 85.417 10048334
Constipation 42 64.919 10010774

Association rows are source-linked signal records, not incidence rates or clinical causality claims.

SOURCE NLM RxNorm 5 name rows

Drug Names / RxNorm

Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.

NameRxCUI TypeSource
sodium benzoate 56455 SU MTHSPL
SODIUM BENZOATE 56455 SU MTHSPL
Sodium Benzoate 56455 SU MTHSPL
Sodium benzoate 56455 SU MTHSPL
sodium benzoate 56455 PIN RXNORM
SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is Sodium Benzoate used for in pharmaceutical contexts?

Sodium Benzoate (CAS 532-32-1) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.

What are the known adverse events for Sodium Benzoate?

Sodium Benzoate has 147 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Creatinine renal clearance decreased, Sedation complication, Blood calcium decreased, Orthostatic hypotension, Cognitive disorder. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is Sodium Benzoate also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for Ingredient compliance data extraction with EU status "permitted".

What clinical phase is Sodium Benzoate in?

Sodium Benzoate is rendered with ChEMBL max phase 4 (approved).

What bioactivity targets are documented for Sodium Benzoate?

Sodium Benzoate has 4 bioactivity rows in this page query. Rendered target entries include Carbonic anhydrase 2, Carbonic anhydrase 4, Carbonic anhydrase.